Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 630Prostatic Neoplasms 372Neoplasms 305Carcinoma, Non-Small-Cell Lung 215Lung Neoplasms 204Colorectal Neoplasms 176Multiple Myeloma 143Pancreatic Neoplasms 136Leukemia, Myeloid, Acute 128Neoplasm Metastasis 124Brain Neoplasms 117Melanoma 116Ovarian Neoplasms 101Carcinoma, Hepatocellular 101Precursor Cell Lymphoblastic Leukemia-Lymphoma 100Glioblastoma 99Uterine Cervical Neoplasms 97Head and Neck Neoplasms 94Squamous Cell Carcinoma of Head and Neck 93Colonic Neoplasms 82Stomach Neoplasms 80Recurrence 80Rectal Neoplasms 80Urinary Bladder Neoplasms 77Sarcoma 77Carcinoma, Renal Cell 76Triple Negative Breast Neoplasms 75Lymphoma 71Lymphoma, Non-Hodgkin 67Leukemia, Lymphocytic, Chronic, B-Cell 66

Interventions

Bumetanide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Unresectable Hepatocellular Carcinoma × Clear all
NCT03107416 2026-05-05

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

Memorial Sloan Kettering Cancer Center

Phase 1/2 Active not recruiting
30 enrolled
Gastrointestinal

Unresectable Hepatocellular Carcinoma

NCT07298538 2025-12-23

Long-Term Survival With Lenvatinib-Based Therapy in Unresectable Liver Cancer

Tianjin Medical University Cancer Institute and Hospital

Active not recruiting
800 enrolled
Gastrointestinal

Unresectable Hepatocellular Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡